Ask about this productRelated genes to: HAPLN4 antibody
- Gene:
- HAPLN4 NIH gene
- Name:
- hyaluronan and proteoglycan link protein 4
- Previous symbol:
- -
- Synonyms:
- BRAL2, KIAA1926
- Chromosome:
- 19p13.11
- Locus Type:
- gene with protein product
- Date approved:
- 2004-03-11
- Date modifiied:
- 2016-10-06
Related products to: HAPLN4 antibody
Related articles to: HAPLN4 antibody
- The triglyceride-glucose (TyG) index, an insulin resistance marker linked to the progression of metabolic dysfunction-associated steatotic liver disease (MASLD), underscores the redox imbalance-mediated crosstalk between MASLD and cardiovascular-liver-metabolic health (CLMH), although its causal mechanisms and molecular drivers remain unresolved. - Source: PubMed
Publication date: 2025/10/07
Wei ShuxuHe LingbinZhang YoutiLi XinyiZhong SuiqinXiao LingShen RonghuaiLu XiaojiaShu ZhouwuQuan YanHuang Xianxi - Circulating proteins play a critical role in rheumatoid arthritis (RA), yet few have been targeted therapeutically. This study aimed to identify novel protein targets for RA therapy. - Source: PubMed
Publication date: 2025/09/25
Ma ZhiqiangChen RanFeng Zibo - This study aimed to investigate the relationship between visceral obesity and various disease traits, as well as to identify potential safe targets for the prevention and treatment of visceral obesity. - Source: PubMed
Zhang GenshanHan BaolinChen YanghuiJiang WeiFu JieXu XiangshangLuo XuelaiCao Zhixin - Neuroblastoma is the most common extracranial solid tumour in children, comprising close to 10% of childhood cancer-related deaths. We have demonstrated that activation of NTRK1 by TP53 repression of PTPN6 expression is significantly associated with favourable survival in neuroblastoma. The molecular mechanisms by which this activation elicits cell molecular changes need to be determined. This is critical to identify dependable biomarkers for the early detection and prognosis of tumours, and for the development of personalised treatment. In this investigation we have identified and validated a gene signature for the prognosis of neuroblastoma using genes differentially expressed upon activation of the NTRK1-PTPN6-TP53 module. A random survival forest model was used to construct a gene signature, which was then assessed across validation datasets using Kaplan-Meier analysis and ROC curves. The analysis demonstrated that high , , , , , , , , , and and low , , , /, , and expression was significantly associated with favourable patient event-free survival (EFS). The gene signature was associated with favourable tumour histology and NTRK1-PTPN6-TP53 module activation. Importantly, all genes were significantly associated with favourable EFS in an independent manner. Six of the signature genes, , /, , , , and , play a role in cell differentiation. Our findings strongly suggest that the identified gene signature is a potential prognostic biomarker and therapeutic target for neuroblastoma patients and that it is associated with neuroblastoma cell differentiation through the activation of the NTRK1-PTPN6-TP53 module. - Source: PubMed
Publication date: 2024/02/08
Currie DavidWong NicoleZane IsabelleRix TomVardakastanis MariosClaxton AmeliaOng Karine K VMacmorland WilliamPoivet ArthurBrooks AnthonyNiola PaolaHuntley DerekMontano Ximena - Modification of the extracellular matrix (ECM) is one of the major processes in the pathology of brain damage following an ischemic stroke. However, our understanding of how age-related ECM alterations may affect stroke pathophysiology and its outcome is still very limited. - Source: PubMed
Publication date: 2023/11/30
Chmelova MartinaAndrovic PeterKirdajova DenisaTureckova JanaKriska JanValihrach LukasAnderova MiroslavaVargova Lydia